PHASE I, OPEN LABEL, ESCALATING DOSETRIAL OF SDZ 969 IN MYELODYSPLASTIC PATIENTS

SDZ 969 在骨髓增生异常患者中的 I 期、开放标签、逐步剂量试验

• 批准号: 3743126
• 负责人: MICHAEL S GORDON
• 金额: --
• 依托单位: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3743126
• 关键词: blood /lymphatic pharmacology; blood cells; blood disorder chemotherapy; bone metabolism; clinical trials; drug screening /evaluation; dyserythropoietic anemia; human subject; human therapy evaluation; immunotherapy; interleukin 6; liver cells; recombinant proteins

Evaluate the effects of rhlL-6 related to hepatocyte, bone metabolism and other hematopoietic and non-hematopoietic cells through an open label, multi-center non-randomized trial.

评价rhIL-6对肝细胞、骨代谢和骨形成的影响。 其他造血和非造血细胞通过开放标签， 多中心非随机试验。